文献速递心力衰竭与心肌病

全基因组测序提升肥厚型心肌病基因检测效能

Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

本研究对58例无亲缘关系的肥厚型心肌病患者、14例患病家属及2例未患病父母进行全基因组测序,检测184个候选心肌肥厚基因编码区、深内含子区、大基因组重排和线粒体基因组变异。在既往基因检测未明确的46个家系中,9个(20%)发现致病或可能致病变异;作为一线检测,12个未检测家系中5个(42%)发现致病变异。全基因组测序较靶向基因测序能发现更多肥厚型心肌病遗传病因,扩展至深内含子区在基因未明确患者中检出9%的致病变异。

要点

  • 全基因组测序在既往检测未明确的肥厚型心肌病家系中额外发现20%的致病变异。
  • 深内含子区变异在基因未明确肥厚型心肌病中占9%,需纳入检测范围。
  • 作为一线检测,全基因组测序在未检测家系中致病变异检出率达42%。

核心结论

  • 全基因组测序较靶向基因测序能发现更多肥厚型心肌病遗传病因。
  • 扩展遗传筛查至深内含子区在基因未明确肥厚型心肌病中检出9%的致病变异。
  • 这些发现有助于肥厚型心肌病家系更准确的诊断和管理。

研究设计与样本

  • 对58例无亲缘关系的肥厚型心肌病患者、14例患病家属和2例未患病父母进行全基因组测序。
  • 检测184个候选心肌肥厚基因编码区、深内含子区、大基因组重排和线粒体基因组变异。
  • 通过RNA分析验证影响剪接的变异。

主要发现

  • 在既往基因检测未明确的46个家系中,9个(20%)发现致病或可能致病变异。
  • 3个家系的变异位于既往检测未包含的基因,1个家系的致病变异被既往外显子测序过滤掉。
  • 5个家系致病变异位于非编码区,包括4个激活新剪接的深内含子变异和1个线粒体基因组变异。
  • 作为一线检测,全基因组测序在12个从未接受基因检测的家系中5个(42%)发现致病变异。

临床怎么用

  • 对既往靶向基因测序未明确的肥厚型心肌病患者,可考虑全基因组测序以发现非编码区及线粒体基因组变异。
  • 全基因组测序作为一线基因检测可提高肥厚型心肌病家系的致病变异检出率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Whole genome sequencing (WGS) is a comprehensive genetic testing approach that reports most types of nucleotide variants. OBJECTIVES: This study sought to assess WGS for hypertrophic cardiomyopathy (HCM) in which prior genetic testing did not establish a molecular diagnosis, and as a first-line genetic test. METHODS: WGS was performed on 58 unrelated patients with HCM, 14 affected family members, and 2 unaffected parents of a severely affected proband. The authors searched for nucleotide variants in coding regions of 184 candidate cardiac hypertrophy genes. They also searched for nucleotide variants in deep intronic regions that alter RNA splicing, large genomic rearrangements, and mitochondrial genome variants. RNA analysis was performed to validate splice-altering variants. RESULTS: The authors found a pathogenic or likely pathogenic variant in 9 of 46 families (20%) for which prior genetic testing was inconclusive. Three families had variants in genes not included in prior genetic testing. One family had a pathogenic variant that was filtered out with prior exome sequencing. Five families had pathogenic variants in noncoding regions, including 4 with deep intronic variants that activate novel splicing, and 1 mitochondrial genome variant. As a first-line genetic test, WGS identified a pathogenic variant in 5 of 12 families (42%) that had never received prior genetic testing. CONCLUSIONS: WGS identified additional genetic causes of HCM over targeted gene sequencing approaches. Extending genetic screening to deep intronic regions identified pathogenic variants in 9% of gene-elusive HCM. These findings translate to more accurate diagnosis and management in HCM families.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Bagnall RD, Ingles J, Dinger ME, et al. Whole Genome Sequencing Improves Outcomes of Genetic Testing in Patients With Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2018. PMID: 30025578. doi:10.1016/j.jacc.2018.04.078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。